3rd Quarter - Report
SPLITOAK STRATEGIES LLC for AMRYT PHARMA
Client
Income
$40,000
Expenses
—
What was lobbied
One issue area, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
HR 4472 the BENEFIT Act; HR 7640 the HEART Act; S 4348 the Food & Drug Administration Safety and Landmark Advancements of 2022; HR 7667 the Food & Drug Administration Amendments of 2022; Ensuring access to treatments for rare disease; Value of rare disease research and development; FDA process improvements for rare disease
Foreign entity interest: Ownership and therefore indirect interest
| Lobbyist | Covered position, as disclosed |
|---|---|
| SARAH KUEHL EGGE New | Legislative Assistant to Senator Bob Kerrey; Senior Budget Analyst for Democratic staff of the Senate Budget Committee (Sen. Kent Conrad); Deputy Staff Director, Joint Select Committee on Deficit Reduction |
| AMY JENSEN New | 1999-2001 Assistant to the Speaker for Policy; 2003-2005 Special Assistant to the President for Legislative Affairs |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.